Review: No Clear Link for Calcium Supplements, CVD

Share this content:
Review: No Clear Link for Calcium Supplements, CVD
Review: No Clear Link for Calcium Supplements, CVD

TUESDAY, Oct. 25, 2016 (HealthDay News) -- Calcium supplements, taken within recommended levels, can be considered safe for the heart, according to new guidelines and an evidence review published online Oct. 25 in the Annals of Internal Medicine.

To develop the new guidelines, the National Osteoporosis Foundation commissioned an updated research review, done by independent researchers at the Tufts University School of Medicine in Boston. The researchers analyzed 31 studies. Four of them were clinical trials, where older adults (mostly women) were randomly assigned to take calcium, with or without vitamin D.

None of those trials showed that supplement users had higher risks of cardiovascular disease, stroke, or death than participants given placebo pills, the researchers found. The rest of the studies the Tufts team analyzed were observational: They looked at the relationship between people's calcium intake, from diet or supplements, and their risk of cardiovascular disease or stroke. Again, the researchers found the studies showed no consistent connection between higher calcium intake and higher cardiovascular risks.

"The preponderance of evidence does not support cardiovascular adverse effects" from calcium supplements, write the authors of an accompanying editorial. But the editorial authors noted that calcium supplements do have side effects and they urged people to take moderate supplement doses, but only if their diets are deficient in calcium.

The National Osteoporosis Foundation funded the review through a grant from Pfizer Consumer Healthcare, which makes calcium supplements.

Clinical Practice Guideline
Evidence Review
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

Artificial Intelligence Promising for CA, Retinopathy Diagnoses

Artificial Intelligence Promising for CA, Retinopathy Diagnoses

Two studies evaluate use; one for breast cancer, the other for diabetic retinopathy

USPSTF Recommends Against Hormone Tx Post Menopause

USPSTF Recommends Against Hormone Tx Post Menopause

Benefits do not outweigh harms of using hormone therapy for prevention of chronic conditions

Omalizumab Ups Efficacy of Multifood Oral Immunotherapy

Omalizumab Ups Efficacy of Multifood Oral Immunotherapy

Findings in multifood allergic pediatric patients

is free, fast, and customized just for you!

Already a member?

Sign In Now »